Erratum: Competing risks model in screening for preeclampsia by serum placental growth factor and soluble fms-like tyrosine kinase-1 at 30-33 weeks' gestation' (Fetal Diagnosis and Therapy (2014) 35 (240-248) DOI: 10.1159/000359968);Competing risks model in screening for preeclampsia by serum placental growth factor and soluble fms-like tyrosine kinase-1 at 30-33 weeks' gestation

Fetal Diagnosis and Therapy

Volumn 35, Issue 4, 2014, Pages 240-248

  Lai, Jonathan ^a   Garcia Tizon Larroca, Santiago ^a   Peeva, Gergana ^a   Poon, Leona C ^a   Wright, David ^b   Nicolaides, Kypros H ^a  

^a KING S COLLEGE HOSPITAL   (United Kingdom)

^b UNIVERSITY OF EXETER MEDICAL SCHOOL   (United Kingdom)

Author keywords

Placental growth factor; Preeclampsia; Pyramid of antenatal care; Soluble fms like tyrosine kinase 1; Third trimester screening

Indexed keywords

PLACENTAL GROWTH FACTOR; VASCULOTROPIN RECEPTOR 1; BIOLOGICAL MARKER; FLT1 PROTEIN, HUMAN; PLACENTA PROTEIN;

ADULT; ARTICLE; BIOCHEMISTRY; CONTROLLED STUDY; DELIVERY; FALSE POSITIVE RESULT; FEMALE; GESTATIONAL AGE; HUMAN; IMMUNOASSAY ANALYZER; MAJOR CLINICAL STUDY; MATERNAL HYPERTENSION; MATERNAL SERUM; MEDICAL HISTORY; PREDICTION; PREECLAMPSIA; PREGNANCY OUTCOME; PRENATAL SCREENING; PRIORITY JOURNAL; SMALL FOR DATE INFANT; SURVIVAL TIME; THIRD TRIMESTER PREGNANCY; BLOOD LEVEL; NEWBORN PERIOD; PRENATAL CARE; RISK ASSESSMENT; SCREENING; BLOOD; PRE-ECLAMPSIA; PREGNANCY; REGRESSION ANALYSIS;

ADULT; BIOMARKERS; FEMALE; GESTATIONAL AGE; HUMANS; PRE-ECLAMPSIA; PREGNANCY; PREGNANCY OUTCOME; PREGNANCY PROTEINS; PREGNANCY TRIMESTER, THIRD; REGRESSION ANALYSIS; RISK ASSESSMENT; VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR-1;

EID: 84900900051     PISSN: 10153837     EISSN: 14219964     Source Type: Journal    
DOI: 10.1159/000360417     Document Type: Erratum

References (33)

1. World Health Organization: Make Every Mother and Child Count. World Health Report, 2005. Geneva, World Health Organization, 2005
2. Confidential Enquiry into Maternal and Child Health (CEMACH) Perinatal Mortality 2006: England, Wales and Northern Ireland. London, CEMACH, 2008
3. Duley L: The global impact of pre-eclampsia and eclampsia. Semin Perinatol 2009; 33: 130-137
4. Bdolah Y, Sukhatme VP, Karumanchi SA: Angiogenic imbalance in the pathophysiology of preeclampsia: Newer insights. Semin Nephrol 2004; 24: 548-556. (Pubitemid 39505044
5. Kleinrouweler C, Wiegerinck M, Ris-Stalpers C, Bossuyt P, van Der Post J, von Dadelszen P, Mol B, Pajkrt E, for the EBM CONNECT Collaboration: Accuracy of circulating placental growth factor, vascular endothelial growth factor, soluble fms-like tyrosine kinase 1 and soluble endoglin in the prediction of pre-eclampsia: A systematic review and meta-Analysis. BJOG 2012; 119: 778-787
6. Verlohren S, Herraiz I, Lapaire O, Schlembach D, Moertl M, Zeisler H, Calda P, Holzgreve W, Galindo A, Engels T, Denk B, Stepan H: The sFlt-1/PlGF ratio in Different types of hypertensive pregnancy disorders and its prognostic potential in preeclamptic patients. Am J Obstet Gynecol 2012; 206: 58. e1-e8
7. Rana S, Powe CE, Salahuddin S, Verlohren S, Perschel FH, Levine RJ, Lim KH, Wenger JB, Thadhani R, Karumanchi SA: Angiogenic factors and the risk of adverse outcomes in women with suspected preeclampsia. Circulation 2012; 125: 911-919
8. Chaiworapongsa T, Romero R, Savasan ZA, Kusanovic JP, Ogge G, Soto E, Dong Z, Tarca A, Gaurav B, Hassan SS: Maternal plasma concentrations of angiogenic/anti-Angiogenic factors are of prognostic value in patients presenting to the obstetrical triage area with the suspicion of preeclampsia. J Matern Fetal Neonatal Med 2011; 24: 1187-207
9. Sibiude J, Guibourdenche J, Dionne MD, Le Ray C, Anselem O, Serreau R, Goffinet F, Tsatsaris V: Placental growth factor for the prediction of adverse outcomes in patients with suspected preeclampsia or intrauterine growth restriction. PLoS One 2012; 7:e50208
10. Chappell LC, Duckworth S, Seed PT, Griffin M, Myers J, Mackillop L, Simpson N, Waugh J, Anumba D, Kenny LC, Redman CW, Shennan AH: Diagnostic accuracy of placental growth factor in women with suspected preeclampsia: A prospective multicenter study. Circulation 2013; 128: 2121-2131
11. Ohkuchi A, Hirashima C, Takahashi K, Suzuki H, Matsubara S, Suzuki M: Onset threshold of the plasma levels of soluble fms-like tyrosine kinase 1/placental growth factor ratio for predicting the imminent onset of preeclampsia within 4 weeks after blood sampling at 19-31 weeks of gestation. Hypertens Res DOI: 10.1038/hr.2013.95
12. Robinson HP, Fleming JE: A critical evaluation of sonar crown rump length measurements. Br J Obstet Gynaecol 1975; 82: 702-710
13. Brown MA, Lindheimer MD, de Swiet M, Van Assche A, Moutquin JM: The classification and diagnosis of the hypertensive disorders of pregnancy: Statement from the International Society for the Study of Hypertension in Pregnancy (ISSHP). Hypertens Pregnancy 2001; 20:IX-XIV
14. Poon LCY, Volpe N, Muto B, Syngelaki A, Nicolaides KH: Birthweight with gestation and maternal characteristics in live births and stillbirths. Fetal Diagn Ther DOI: 10.1159/000338655
15. Wright D, Akolekar R, Syngelaki A, Poon LC, Nicolaides KH: A competing risks model in early screening for preeclampsia. Fetal Diagn Ther 2012; 32: 171-178
16. Akolekar R, Syngelaki A, Poon L, Wright D, Nicolaides KH: Competing risks model in early screening for preeclampsia by biophysical and biochemical markers. Fetal Diagn Ther 2013; 33: 8-15
17. Tayyar A, Garcia-Tizon Larroca S, Poon LC, Wright D, Nicolaides KH: Competing risks model in screening for preeclampsia by mean arterial pressure and uterine artery pulsatility index at 30-33 weeks' gestation. Fetal Diagn Ther 2013; 33: 8-15
18. Kalbfleisch JD, Prentice RL: The Statistical Analysis of Failure Time Data, ed 2. New York, Wiley, 2002
19. R Core Team: R: A language and environment for statistical computing. Vienna, R Foundation for Statistical Computing, 2013. http:// www.R-project.org/.
20. Khong TY, De Wolf F, Robertson WB, Brosens I: Inadequate maternal vascular response to placentation in pregnancies complicated by pre-eclampsia and by small-for-gestational age infants. BJOG 1986; 93: 1049-1059. (Pubitemid 16004866
21. Pijnenborg R, Anthony J, Davey DA, Rees A, Tiltman A, Vercruysse L, van Assche A: Placental bed spiral arteries in the hypertensive disorders of pregnancy. BJOG 1991; 98: 648-655
22. Torry DS, Mukherjea D, Arroyo J, Torry RJ: Expression and function of placenta growth factor: Implications for abnormal placentation. J Soc Gynecol Investig 2003; 10: 178-188. (Pubitemid 36579239
23. Munaut C, Lorquet S, Pequeux C, Blacher S, Berndt S, Frankenne F, Foidart JM: Hypoxia is responsible for soluble vascular endothelial growth factor receptor-1 (VEGFR-1) but not for soluble endoglin induction in villous trophoblast. Hum Reprod 2008; 23: 1407-1415. (Pubitemid 351770590
24. Maynard SE, Min JY, Merchan J, Lim KH, Li J, Mondal S, Libermann TA, Morgan JP, Sellke FW, Stillman IE, Epstein FH, Sukhatme VP, Karumanchi SA: Excess placental soluble fms-like tyrosine kinase 1 (sFlt1) may contribute to endothelial dysfunction, hypertension, and proteinuria in preeclampsia. J Clin Invest 2003; 111: 649-658. (Pubitemid 36278583
25. Chaiworapongsa T, Romero R, Korzeniewski SJ, Kusanovic JP, Soto E, Lam J, Dong Z, Than NG, Yeo L, Hernandez-Andrade E, Conde-Agudelo A, Hassan SS: Maternal plasma concentrations of angiogenic/antiangiogenic factors in the third trimester of pregnancy to identify the patient at risk for stillbirth at or near term and severe late preeclampsia. Am J Obstet Gynecol 2013; 208: 287.e1-287.e15
26. Nicolaides KH: Turning the pyramid of prenatal care. Fetal Diagn Ther 2011; 29: 183-196
27. Poon LC, Kametas NA, Maiz N, Akolekar R, Nicolaides KH: First-Trimester prediction of hypertensive disorders in pregnancy. Hypertension 2009; 53: 812-818
28. Bujold E, Roberge S, Lacasse Y, Bureau M, Audibert F, Marcoux S, Forest JC, Giguere Y: Prevention of preeclampsia and intrauterine growth restriction with aspirin started in early pregnancy: A meta-Analysis. Obstet Gynecol 2010; 116: 402-414
29. Roberge S, Villa P, Nicolaides K, Giguere Y, Vainio M, Bakthi A, Ebrashy A, Bujold E: Early administration of low dose aspirin for the prevention of preterm and term pre-eclampsia: A systematic review and meta-Analysis. Fetal Diagn Ther 2012; 31: 141-146
30. Koopmans CM, Bijlenga D, Groen H, Vijgen SM, Aarnoudse JG, Bekedam DJ, van Den Berg PP, de Boer K, Burggraaff JM, Bloemenkamp KW, Drogtrop AP, Franx A, de Groot CJ, Huisjes AJ, Kwee A, van Loon AJ, Lub A, Papatsonis DN, van Der Post JA, Roumen FJ, Scheepers HC, Willekes C, Mol BW, van Pampus MG; HYPITAT study group: Induction of labour versus expectant monitoring for gestational hypertension or mild pre-eclampsia after 36 weeks' gestation (HYPITAT): A multicentre, open-label randomised controlled trial. Lancet 2009; 374: 979-988
31. Kumasawa K, Ikawa M, Kidoya H, Hasuwa H, Saito-Fujita T, Morioka Y, Takakura N, Kimura T, Okabe M: Pravastatin induces placental growth factor (PGF) and ameliorates preeclampsia in a mouse model. Proc Natl Acad Sci USA 2011; 108: 1451-1455
32. Li Z, Zhang Y, Ying Ma J, Kapoun AM, Shao Q, Kerr I, Lam A, O'Young G, Sannajust F, Stathis P, Schreiner G, Karumanchi SA, Protter AA, Pollitt NS: Recombinant vascular endothelial growth factor 121 attenuates hypertension and improves kidney damage in a rat model of preeclampsia. Hypertension 2007; 50: 686-692. (Pubitemid 47442732
33. Thadhani R, Kisner T, Hagmann H, Bossung V, Noack S, Schaarschmidt W, Jank A, Kribs A, Cornely OA, Kreyssig C, Hemphill L, Rigby AC, Khedkar S, Lindner TH, Mallmann P, Stepan H, Karumanchi SA, Benzing T: Pilot study of extracorporeal removal of soluble fms-like tyrosine kinase 1 in preeclampsia. Circulation 2011; 124: 940-950.